Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials

Aiman J Faruqi; John A Ligon; Julia W Cohen; Srivandana Akshintala; Brigitte C Widemann; Nirali N Shah

doi:10.1093/oncolo/oyac124

Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials

Oncologist. 2022 Aug 5;27(8):e681-e682. doi: 10.1093/oncolo/oyac124.

Authors

Aiman J Faruqi^{1

2}, John A Ligon^{1

3}, Julia W Cohen^{1

4}, Srivandana Akshintala¹, Brigitte C Widemann¹, Nirali N Shah¹

Affiliations

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
² Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
³ Division of Hematology/Oncology, Department of Pediatrics, University of Florida, Gainesville, FL, USA.
⁴ Merck and Co, Inc., Kenilworth, New Jersey, USA.

Abstract

This letter to the editor considers outcomes for underrepresented populations across early phase pediatric oncology clinical trials, considering barriers to equitable representation of minorities in clinical trials.

Publication types

Research Support, Non-U.S. Gov't
Letter
Research Support, N.I.H., Intramural
Research Support, N.I.H., Extramural

MeSH terms

Child
Ethnic and Racial Minorities
Ethnicity*
Humans
Minority Groups
Neoplasms* / therapy
Racial Groups
United States

Grants and funding

ZIA BC011823/ImNIH/Intramural NIH HHS/United States